Last reviewed · How we verify
iv Amiodarone
Amiodarone blocks cardiac potassium, sodium, calcium, and beta-adrenergic channels to slow electrical conduction and suppress arrhythmias.
Amiodarone blocks cardiac potassium, sodium, calcium, and beta-adrenergic channels to slow electrical conduction and suppress arrhythmias. Used for Atrial fibrillation with rapid ventricular response, Ventricular tachycardia, Ventricular fibrillation.
At a glance
| Generic name | iv Amiodarone |
|---|---|
| Sponsor | Hospital General Universitario Gregorio Marañon |
| Drug class | Class III antiarrhythmic agent |
| Target | Potassium channels (hERG), sodium channels, calcium channels, beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amiodarone is a Class III antiarrhythmic agent that primarily blocks potassium channels and prolongs the action potential duration and refractory period. It also has properties of Classes I, II, and IV antiarrhythmics, blocking sodium and calcium channels and beta-adrenergic receptors, making it a broad-spectrum antiarrhythmic effective for both atrial and ventricular arrhythmias.
Approved indications
- Atrial fibrillation with rapid ventricular response
- Ventricular tachycardia
- Ventricular fibrillation
- Supraventricular tachycardia refractory to other agents
Common side effects
- Hypotension
- Bradycardia
- Phlebitis at injection site
- Nausea
- Pulmonary toxicity (chronic use)
- Thyroid dysfunction (chronic use)
- Hepatotoxicity
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment (PHASE4)
- Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial (NA)
- Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence (PHASE4)
- Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer (PHASE2)
- Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery (PHASE3)
- Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response (PHASE4)
- Utility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Software: a Prospective Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iv Amiodarone CI brief — competitive landscape report
- iv Amiodarone updates RSS · CI watch RSS
- Hospital General Universitario Gregorio Marañon portfolio CI